Pharmacological Evaluation of SN79, a Sigma (σ) Receptor Ligand, Against Methamphetamine-induced Neurotoxicity in Vivo

Overview

Journal Eur Neuropsychopharmacol

Publisher Elsevier

Specialties Pharmacology
Psychiatry

Date 2012 Aug 28

PMID 22921523

Citations 18

Authors

Nidhi Kaushal

Michael J Seminerio

Matthew J Robson

Christopher R McCurdy

Rae R Matsumoto

Affiliations

Soon will be listed here.

Abstract

Methamphetamine is a highly addictive psychostimulant drug of abuse, causing hyperthermia and neurotoxicity at high doses. Currently, there is no clinically proven pharmacotherapy to treat these effects of methamphetamine, necessitating identification of potential novel therapeutic targets. Earlier studies showed that methamphetamine binds to sigma (σ) receptors in the brain at physiologically relevant concentrations, where it "acts in part as an agonist." SN79 (6-acetyl-3-(4-(4-(4-florophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one) was synthesized as a putative σ receptor antagonist with nanomolar affinity and selectivity for σ receptors over 57 other binding sites. SN79 pretreatment afforded protection against methamphetamine-induced hyperthermia and striatal dopaminergic and serotonergic neurotoxicity in male, Swiss Webster mice (measured as depletions in striatal dopamine and serotonin levels, and reductions in striatal dopamine and serotonin transporter expression levels). In contrast, di-o-tolylguanidine (DTG), a well established σ receptor agonist, increased the lethal effects of methamphetamine, although it did not further exacerbate methamphetamine-induced hyperthermia. Together, the data implicate σ receptors in the direct modulation of some effects of methamphetamine such as lethality, while having a modulatory role which can mitigate other methamphetamine-induced effects such as hyperthermia and neurotoxicity.

Citing Articles

Methamphetamine-mediated astrocytic pyroptosis and neuroinflammation involves miR-152-NLRP6 inflammasome signaling axis.

Oladapo A, Kannan M, Deshetty U, Singh S, Buch S, Periyasamy P Redox Biol. 2025; 80:103517.

PMID: 39879739 PMC: 11810843. DOI: 10.1016/j.redox.2025.103517.

Neurotoxicity of methamphetamine: Main effects and mechanisms.

Jayanthi S, Daiwile A, Cadet J Exp Neurol. 2021; 344:113795.

PMID: 34186102 PMC: 8338805. DOI: 10.1016/j.expneurol.2021.113795.

Association of sigma-1 receptor with dopamine transporter attenuates the binding of methamphetamine via distinct helix-helix interactions.

Xu L, Chen L Chem Biol Drug Des. 2021; 97(6):1194-1209.

PMID: 33754484 PMC: 8113090. DOI: 10.1111/cbdd.13841.

Cannabidiol attenuates methamphetamine-induced conditioned place preference via the Sigma1R/AKT/GSK-3β/CREB signaling pathway in rats.

Yang G, Liu L, Zhang R, Li J, Leung C, Huang J Toxicol Res (Camb). 2020; 9(3):202-211.

PMID: 32670551 PMC: 7329178. DOI: 10.1093/toxres/tfaa021.

Benzimidazolone-based selective σ receptor ligands: Synthesis and pharmacological evaluation.

Intagliata S, Alsharif W, Mesangeau C, Fazio N, Seminerio M, Xu Y Eur J Med Chem. 2019; 165:250-257.

PMID: 30685525 PMC: 6369001. DOI: 10.1016/j.ejmech.2019.01.019.

References

Kita T, Matsunari Y, Saraya T, Shimada K, Ohara K, Kubo K . Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice. Int J Dev Neurosci. 2000; 18(6):521-30. DOI: 10.1016/s0736-5748(00)00022-8. View

Matsumoto R, Shaikh J, Wilson L, Vedam S, Coop A . Attenuation of methamphetamine-induced effects through the antagonism of sigma (sigma) receptors: Evidence from in vivo and in vitro studies. Eur Neuropsychopharmacol. 2008; 18(12):871-81. PMC: 2688716. DOI: 10.1016/j.euroneuro.2008.07.006. View

Baldwin H, Colado M, Murray T, de Souza R, Green A . Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br J Pharmacol. 1993; 108(3):590-6. PMC: 1908047. DOI: 10.1111/j.1476-5381.1993.tb12847.x. View

Numachi Y, Ohara A, Yamashita M, Fukushima S, Kobayashi H, Hata H . Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters. Eur J Pharmacol. 2007; 572(2-3):120-8. DOI: 10.1016/j.ejphar.2007.06.022. View

Fukumura M, Cappon G, Pu C, Broening H, Vorhees C . A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 1998; 806(1):1-7. DOI: 10.1016/s0006-8993(98)00656-8. View

Kaushal N, Seminerio M, Shaikh J, Medina M, Mesangeau C, Wilson L . CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice. Neuropharmacology. 2011; 61(5-6):992-1000. PMC: 3615888. DOI: 10.1016/j.neuropharm.2011.06.028. View

van Waarde A, Rybczynska A, Ramakrishnan N, Ishiwata K, Elsinga P, Dierckx R . Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharm Des. 2010; 16(31):3519-37. DOI: 10.2174/138161210793563365. View

Cruickshank C, Dyer K . A review of the clinical pharmacology of methamphetamine. Addiction. 2009; 104(7):1085-99. DOI: 10.1111/j.1360-0443.2009.02564.x. View

Brunswick D, Benmansour S, Tejani-Butt S, Hauptmann M . Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography. Synapse. 1992; 11(4):287-93. DOI: 10.1002/syn.890110404. View

10.

Kaushal N, Elliott M, Robson M, Iyer A, Rojanasakul Y, Coop A . AC927, a σ receptor ligand, blocks methamphetamine-induced release of dopamine and generation of reactive oxygen species in NG108-15 cells. Mol Pharmacol. 2011; 81(3):299-308. PMC: 3286303. DOI: 10.1124/mol.111.074120. View

11.

Mishina M, Ishiwata K, Ishii K, Kitamura S, Kimura Y, Kawamura K . Function of sigma1 receptors in Parkinson's disease. Acta Neurol Scand. 2005; 112(2):103-7. DOI: 10.1111/j.1600-0404.2005.00432.x. View

12.

Kaushal N, Matsumoto R . Role of sigma receptors in methamphetamine-induced neurotoxicity. Curr Neuropharmacol. 2011; 9(1):54-7. PMC: 3137201. DOI: 10.2174/157015911795016930. View

13.

Fleckenstein A, Wilkins D, GIBB J, Hanson G . Interaction between hyperthermia and oxygen radical formation in the 5-hydroxytryptaminergic response to a single methamphetamine administration. J Pharmacol Exp Ther. 1997; 283(1):281-5. View

14.

Gough B, Imam S, Blough B, Slikker Jr W, Ali S . Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study. Ann N Y Acad Sci. 2002; 965:410-20. DOI: 10.1111/j.1749-6632.2002.tb04182.x. View

15.

Xie T, McCann U, Kim S, Yuan J, Ricaurte G . Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci. 2000; 20(20):7838-45. PMC: 6772867. View

16.

Kuczenski R, Segal D, Cho A, Melega W . Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci. 1995; 15(2):1308-17. PMC: 6577819. View

17.

Hirata H, Ladenheim B, Rothman R, Epstein C, Cadet J . Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals. Brain Res. 1995; 677(2):345-7. DOI: 10.1016/0006-8993(95)00218-f. View

18.

Robson M, Noorbakhsh B, Seminerio M, Matsumoto R . Sigma-1 receptors: potential targets for the treatment of substance abuse. Curr Pharm Des. 2012; 18(7):902-19. DOI: 10.2174/138161212799436601. View

19.

Nguyen E, McCracken K, Liu Y, Pouw B, Matsumoto R . Involvement of sigma (sigma) receptors in the acute actions of methamphetamine: receptor binding and behavioral studies. Neuropharmacology. 2005; 49(5):638-45. DOI: 10.1016/j.neuropharm.2005.04.016. View

20.

Cappon G, Pu C, Vorhees C . Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment. Brain Res. 2000; 863(1-2):106-11. DOI: 10.1016/s0006-8993(00)02107-7. View